NDA 208259/S-006

SUPPLEMENT APPROVAL AND FULFILLMENT OF POSTMARKETING COMMITMENT

Aerie Pharmaceuticals, Inc.
Attention: George Baklayan, Director
Regulatory Affairs / Technical Writing
2030 Main St., Suite 1400
Irvine, CA 92614

Dear Mr. Baklayan:

Please refer to your supplemental new drug application (sNDA) dated and received March 13, 2020, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for ROCKLATAN (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. This Prior Approval supplemental new drug application proposes to update the Drug Interactions section of the Prescribing Information to describe that *in vitro* studies have shown that precipitation can occur when eye drops containing thimerosal are mixed with ROCKLATAN.

APPROVAL & LABELING

We have completed our review of this application. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.[1] Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.[2] The SPL will be accessible from publicly available labeling repositories.

CARTON AND CONTAINER LABELING

Submit final printed carton and container labeling that are identical to the carton and container labeling submitted on January 10, 2020, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically

[1] http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm
[2] We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission "**Final Printed Carton and Container Labeling for approved NDA 208259/S-003**." Approval of this submission by FDA is not required before the labeling is used.

FULFILLMENT OF POSTMARKETING COMMITMENT

We have received your submission dated March 13, 2020, containing the final report for the following postmarketing commitment listed in the March 12, 2019, approval letter.

3584-1 To conduct an in vitro study to determine if the precipitation occurs when eye drops containing thimerosal are mixed with Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%.

We have reviewed your submission and conclude that the above commitment was fulfilled.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Derek Alberding, Regulatory Health Project Manager, at (240) 402-0963.

Sincerely,

{See appended electronic signature page}

Wiley A. Chambers, M.D.
(Acting) Director
Division of Ophthalmology
Office of Specialty Medicine
Center for Drug Evaluation and Research

ENCLOSURE:

- Content of Labeling
    - Prescribing Information

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

WILEY A CHAMBERS
06/01/2020 04:06:54 PM